

Fig. 2. Alignment of NS5A region around IRRDR aa.2340-2382, along with SVR.

distinct correlation with the final outcomes in our study group (SVR rate: 100%, 80%, 20%, and 0% for RVR, cEVR, pEVR, and nEVR in standard therapy). These results demonstrated that classification by viral response at week 12 provides distinct groups with different characteristics.

We first tried to identify regions of the HCV ORF by showing a distinct linkage to RVR and nEVR. We found that HCV substitutions around the ISDR (aa.2224-2248 in RVR) were most significantly correlated with early viral clearance in Peg-IFN/RBV therapy. In contrast, core aa:70 substitution was most sig-

nificantly correlated with nEVR, demonstrating the association with treatment resistance. According to the results shown here, early HCV dynamics in Peg-IFN/RBV therapy are significantly regulated by the specific viral sequences in core and NS5A (Fig. 1A,B).

Next, we determined that HCV genomic region correlated with SVR of patients with standard therapy. We excluded patients with extended therapy to unify treatment duration. Considering the length of treatment, we first suspected that multiple factors might affect the final outcome of 48 weeks of standard therapy, and that determining viral regions reflecting pure




Fig. 3. Roles of three HCV-1b viral regions in the determination of time-dependent treatment response to Peg-IFN/RBV therapy.

biological response would be difficult. Contrary to our prediction, a region almost identical to the IRRDR (aa.2340-2382) was extracted by systematic sliding analysis as correlated with outcome, with a significantly high *P* value, demonstrating the remarkable influence of the IRRDR aa.2340-2382 in determining final outcome (Fig. 1C). Importantly, in addition to final outcome, when relapser and nonrelapser in the ETR were compared, aa.2360-2377, the region almost coinciding with the V3 region of the IRRDR, was extracted as the region discriminating these two groups (Fig. 1D).

In the analysis of IL28B SNPs (rs8099917), we observed a significant correlation between IL28B SNP and viral dynamics at week 12; patients with minor/minor or minor/major alleles showed significantly poor responses, as demonstrated in Table 2. On the other hand, because poor response was significantly associated with the substitution of the core aa.70 (as shown in Fig. 1B) in our study, we next tried to unveil the correlation between HCV ORF and IL28B SNPs. The significant link with the single core aa.70 substitution was observed through searching for the complete HCV ORFs (Supporting Fig. 1). The result coincides with recent studies²⁷⁻²⁹ and, moreover, confirms that this single spot is extraordinarily linked to the initial poor response among the complete 3,010 HCV aa residues. Though the underlying mechanism for the association of IL28B and core aa.70 is unclear, the association would be a reflection of an interaction between the IL28B SNPs and HCV sequences in the development of chronic HCV infection, as discussed by Kurosaki et al.²⁹ Namely, it is possible that HCV sequences within the patient might have been selected during the course of chronic infection, depending on the IL28B SNPs, by selective pressures of unknown mechanism.

By multivariate analysis, IL28B SNP, IRRDR aa.2340-2382, and ISDR aa.2224-2248 were extracted as independent variables related to final outcome in patients with standard length of therapy with the inclusion of an additional 30 patients (Table 5). Among these, IL28B SNPs and IRRDR aa.2340-2382 were the two most-significant variables determining final outcome. Moreover, NS5A IRRDR aa.2340-2379 (~2382) was the most-significant viral region contributing to final outcome in patients with IL28B TT haplotype (*P* = 2.47E-05), demonstrating that combined information of the IL28B and IRRDR is significantly important in predicting viral kinetics and treatment outcome (Fig. 1D).

Most of the viral genomic regions identified in this study have already been reported on in previous, inde-

pendent studies. However, the importance of our study is shown in the result that these specific viral regions of core, ISDR, and IRRDR were extracted all at once through systematic full HCV ORF sequence screening. What is unique in our study is the introduction of the sliding-window analysis; through this analysis, we could effectively confine viral regions of ISDR and IRRDR that were not identified in other previous HCV ORF studies.^{21,22} Furthermore, our study also disclosed that the importance of these viral regions was different according to each treatment-phase; RVR, nEVR, SVR, and relapse were mostly related to the ISDR, core aa.70, the IRRDR, and IRRDR, respectively. The ISDR was the first region identified as being related to SVR in the era of IFN monotherapy in Japanese patients, such that multiple mutations in the ISDR were associated with favorable IFN responses.^{10,30} The contribution of the core region in treatment response in IFN/RBV therapy was first reported on by Akuta et al., in that the polymorphisms of core aa.70 and 91 were closely related to final outcome.²⁰ The further significance of core polymorphism was reported on in hepatocarcinogenesis as well.^{31,32} Our analysis also confirmed the recent studies reporting on the close correlation between viral core and IL28B SNPs.^{11,29,32} The present finding that the core aa.70 is correlated with nEVR independently of IL28B seems to reflect the recent report that core aa.70 is an independent determinant of poor response to the triple therapy of Peg-IFN/RBV and telaprevir in patients with the IL28B minor allele.²⁷ On the other hand, the IRRDR was originally reported on by El-Shamy et al. as being related to the result of Peg-IFN/RBV therapy.¹⁵ Importantly, our study revealed that final SVR and relapse were significantly correlated with mutations around the IRRDR. The result indicates its significant role in late-phase viral responses in Peg-IFN/RBV therapy.

Core is a main-component protein of viral nucleocapsid, and it has recently been found that the core located on the surface of lipid droplets associates with NS5A to facilitate virion formation.³³ HCV-JFH1 with core R70Q/H and L91M was reported to impair virion formation resulting in the accumulation of intracellular core protein, which causes endoplasmic reticulum stress leading to IFN resistance through suppressor of cytokine signaling 3 up-regulation induced by IL-6.³⁴ NS5A is a phosphoprotein and is considered to play a pivotal role both in viral replication and virion production, depending on its phosphorylation state.³⁵⁻³⁷ Mutations in centrally located serine residues required for NS5A hyperphosphorylation as well as in

its adjacently located ISDR work as adaptive mutations in the HCV replicon, possibly through decreasing the hyperphosphorylated form of NS5A,³⁷⁻⁴⁰ which seems to control HCV replication. The conservation of c-terminal serine residual cluster of NS5A, downstream to IRRDR, is required for NS5A basal phosphorylation, interaction with the core protein on the lipid droplet, and thus virion formation.^{41,42} Taken together, it can be speculated that the structural changes in core and NS5A protein can coordinately modify HCV replication, especially through virion formation around lipid droplets. However, the precise mechanism through which these modulations of viral proteins lead to the different treatment response should be further investigated.

In conclusion, we have found that polymorphic viral sequences in core aa.70, NS5A-ISDR aa.2224-2248, and NS5A-IRRDR aa.2340-2382 in genotype 1b HCV infection are correlated significantly with the treatment phase-specific viral responses to Peg-IFN/RBV therapy. In addition, these viral responses were also significantly correlated with the polymorphism in IL28B SNP, and this polymorphism was significantly correlated with the polymorphism in the core. More important, combined information of IL28B and IRRDR aa.2340-2382 is significantly important in predicting viral kinetics and treatment outcome. We consider that our comprehensive study provides a new basis for introducing Peg-IFN/RBV therapy as well as a new generation of anti-HCV therapies.

References

- Lavanchy D. The global burden of hepatitis C. *Liver Int* 2009; 29(Suppl 1):74-81.
- McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, McCone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. *N Engl J Med* 2009;361:580-593.
- Fried MW. The role of triple therapy in HCV genotype 1-experienced patients. *Liver Int* 2011;31(Suppl 1):58-61.
- Walsh MJ, Jonsson JR, Richardson MM, Lipka GM, Purdie DM, Clouston AD, Powell EE. Non-response to antiviral therapy is associated with obesity and increased hepatic expression of suppressor of cytokine signalling 3 (SOCS-3) in patients with chronic hepatitis C, viral genotype 1. *Gut* 2006;55:529-535.
- Missiha S, Heathcote J, Arenovich T, Khan K; Canadian Pegasys Expanded Access G. Impact of asian race on response to combination therapy with peginterferon alfa-2a and ribavirin in chronic hepatitis C. *Am J Gastroenterol* 2007;102:2181-2188.
- Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. *Nature* 2009;461:399-401.
- Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, Abate ML, et al. IL28B is associated with response to chronic hepatitis C interferon- and ribavirin therapy. *Nat Genet* 2009;41:1100-1104.
- Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, Sakamoto N, et al. Genome-wide association of IL28B with response to pegylated interferon- and ribavirin therapy for chronic hepatitis C. *Nat Genet* 2009;41:1105-1109.
- Zeuzem S, Rizzetto M, Ferenci P, Shiffman ML. Management of hepatitis C virus genotype 2 or 3 infection: treatment optimization on the basis of virological response. *Antivir Ther* 2009;14:143-154.
- Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. *J Clin Invest* 1995;96:224-230.
- Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. *Gut* 2011;60:261-267.
- Murphy MD, Rosen HR, Marousek GI, Chou S. Analysis of sequence configurations of the ISDR, PKR-binding domain, and V3 region as predictors of response to induction interferon-alpha and ribavirin therapy in chronic hepatitis C infection. *Dig Dis Sci* 2002;47:1195-1205.
- Sarrazin C, Berg T, Lee JH, Ruster B, Kronenberger B, Roth WK, Zeuzem S. Mutations in the protein kinase-binding domain of the NS5A protein in patients infected with hepatitis C virus type 1a are associated with treatment response. *J Infect Dis* 2000;181:432-441.
- Duverlie G, Khorsi H, Castelain S, Jaillon O, Izoper J, Lunel F, et al. Sequence analysis of the NS5A protein of European hepatitis C virus 1b isolates and relation to interferon sensitivity. *J Gen Virol* 1998;79:1373-1381.
- El-Shamy A, Nagano-Fujii M, Sasase N, Imoto S, Kim SR, Hotta H. Sequence variation in hepatitis C virus nonstructural protein 5A predicts clinical outcome of pegylated interferon/ribavirin combination therapy. *HEPATOLOGY* 2008;48:38-47.
- Taylor DR, Shi ST, Romano PR, Barber GN, Lai MM. Inhibition of the interferon-inducible protein kinase PKR by HCV E2 protein. *Science* 1999;285:107-110.
- Pfeiffer JK, Kirkegaard K. Ribavirin resistance in hepatitis C virus replicon-containing cell lines conferred by changes in the cell line or mutations in the replicon RNA. *J Virol* 2005;79:2346-2355.
- Young KC, Lindsay KL, Lee KJ, Liu WC, He JW, Milstein SL, Lai MM. Identification of a ribavirin-resistant NS5B mutation of hepatitis C virus during ribavirin monotherapy. *HEPATOLOGY* 2003;38:869-878.
- Hamano K, Sakamoto N, Enomoto N, Izumi N, Asahina Y, Kurosaki M, et al. Mutations in the NS5B region of the hepatitis C virus genome correlate with clinical outcomes of interferon-alpha plus ribavirin combination therapy. *J Gastroenterol Hepatol* 2005;20:1401-1409.
- Akuta N, Suzuki F, Sezaki H, Suzuki Y, Hosaka T, Someya T, et al. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. *Intervirology* 2005;48:372-380.
- Donlin MJ, Cannon NA, Aurora R, Li J, Wahed AS, Di Bisceglie AM, et al. Contribution of genome-wide HCV genetic differences to outcome of interferon-based therapy in Caucasian American and African American patients. *PLoS One* 2010;5:e9032.
- Donlin MJ, Cannon NA, Yao E, Li J, Wahed A, Taylor MW, et al. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. *J Virol* 2007;81:8211-8224.
- Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. *J Hepatol* 2011;54:439-448.
- Enomoto N, Maekawa S. HCV genetic elements determining the early response to peginterferon and ribavirin therapy. *Intervirology* 2010;53:66-69.
- Nagayama K, Kurosaki M, Enomoto N, Maekawa SY, Miyasaka Y, Tazawa J, et al. Time-related changes in full-length hepatitis C virus sequences and hepatitis activity. *Virology* 1999;263:244-253.

26. Lee SS, Ferenci P. Optimizing outcomes in patients with hepatitis C virus genotype 1 or 4. *Antivir Ther* 2008;13(Suppl 1):9-16.
27. Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. *HEPATOLOGY* 2010;52:421-429.
28. Hayes CN, Kobayashi M, Akuta N, Suzuki F, Kumada H, Abe H, et al. HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy. *Gut* 2010;60:261-267.
29. Kurosaki M, Tanaka Y, Nishida N, Sakamoto N, Enomoto N, Honda M, et al. Pre-treatment prediction of response to pegylated-interferon plus ribavirin for chronic hepatitis C using genetic polymorphism in IL28B and viral factors. *J Hepatol* 2010;54:439-448.
30. Enomoto N, Sakuma I, Asahina Y, Kurosaki M, Murakami T, Yamamoto C, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. *N Engl J Med* 1996;334:77-81.
31. Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, et al. Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis. *HEPATOLOGY* 2007;46:1357-1364.
32. Miura M, Maekawa S, Kadokura M, Sueki R, Komase K, Shindo H, et al. Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C. *Hepatol Int* 2011 Aug 17. doi no.: 10.1007/s12072-011-9307-6.
33. Miyanari Y, Atsuzawa K, Usuda N, Watashi K, Hishiki T, Zayas M, et al. The lipid droplet is an important organelle for hepatitis C virus production. *Nat Cell Biol* 2007;9:1089-1097.
34. Funaoka Y, Sakamoto N, Suda G, Itsui Y, Nakagawa M, Kakinuma S, et al. Analysis of interferon signaling by infectious hepatitis C virus clones with substitutions of core amino acids 70 and 91. *J Virol* 2011; 85:5986-5994.
35. Huang Y, Staschke K, De Francesco R, Tan SL. Phosphorylation of hepatitis C virus NS5A nonstructural protein: a new paradigm for phosphorylation-dependent viral RNA replication? *Virology* 2007;364:1-9.
36. Macdonald A, Harris M. Hepatitis C virus NS5A: tales of a promiscuous protein. *J Gen Virol* 2004;85:2485-2502.
37. Moradpour D, Penin F, Rice CM. Replication of hepatitis C virus. *Nat Rev Microbiol* 2007;5:453-463.
38. Blight KJ, Kolykhalov AA, Rice CM. Efficient initiation of HCV RNA replication in cell culture. *Science* 2000;290:1972-1974.
39. Maekawa S, Enomoto N, Sakamoto N, Kurosaki M, Ueda E, Kohashi T, et al. Introduction of NS5A mutations enables subgenomic HCV replicon derived from chimpanzee-infectious HC-J4 isolate to replicate efficiently in Huh-7 cells. *J Viral Hepat* 2004;11:394-403.
40. Kohashi T, Maekawa S, Sakamoto N, Kurosaki M, Watanabe H, Tanabe Y, et al. Site-specific mutation of the interferon sensitivity-determining region (ISDR) modulates hepatitis C virus replication. *J Viral Hepat* 2006;13:582-590.
41. Masaki T, Suzuki R, Murakami K, Aizaki H, Ishii K, Murayama A, et al. Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. *J Virol* 2008;82:7964-7976.
42. Tellinghuisen TL, Foss KL, Treadaway J. Regulation of hepatitis C virion production via phosphorylation of the NS5A protein. *PLoS Pathog* 2008;4:e1000032.

IL-28B (IFN- λ 3) and IFN- α synergistically inhibit HCV replication

H. Shindo,¹ S. Maekawa,¹ K. Komase,¹ M. Miura,¹ M. Kadokura,¹ R. Sueki,¹ N. Komatsu,¹ K. Shindo,¹ F. Amemiya,¹ Y. Nakayama,¹ T. Inoue,¹ M. Sakamoto,¹ A. Yamashita,² K. Moriishi² and N. Enomoto¹ ¹First Department of Internal Medicine, University of Yamanashi, Yamanashi, Japan; and ²Department of Microbiology, University of Yamanashi, Yamanashi, Japan

Received March 2012; accepted for publication June 2012

SUMMARY. Genetic variation in the IL-28B (interleukin-28B; interferon lambda 3) region has been associated with sustained virological response (SVR) rates in patients with chronic hepatitis C treated with peginterferon- α and ribavirin. However, the mechanisms by which polymorphisms in the IL-28B gene region affect host antiviral responses are not well understood. Using the HCV 1b and 2a replicon system, we compared the effects of IFN- λ s and IFN- α on HCV RNA replication. The anti-HCV effect of IFN- λ 3 and IFN- α in combination was also assessed. Changes in gene expression induced by IFN- λ 3 and IFN- α were compared using cDNA microarray analysis. IFN- λ s at concentrations of 1 ng/mL or more exhibited concentration- and time-dependent HCV inhibition. In combination, IFN- λ 3 and IFN- α had a synergistic anti-HCV effect; however, no synergistic enhancement was observed for

interferon-stimulated response element (ISRE) activity or upregulation of interferon-stimulated genes (ISGs). With respect to the time course of ISG upregulation, the peak of IFN- λ 3-induced gene expression occurred later and lasted longer than that induced by IFN- α . In addition, although the genes upregulated by IFN- α and IFN- λ 3 were similar to microarray analysis, interferon-stimulated gene expression appeared early and was prolonged by combined administration of these two IFNs. In conclusion, IFN- α and IFN- λ 3 in combination showed synergistic anti-HCV activity *in vitro*. Differences in time-dependent upregulation of these genes might contribute to the synergistic antiviral activity.

Keywords: HCV, IFN- λ , IL-28B, ISG, synergistic inhibition, microarray.

INTRODUCTION

In 2009, reports from three genome-wide association studies revealed that several single-nucleotide polymorphisms (SNPs) (rs12979860, rs12980275 and rs8099917) around the IL-28B (interleukin-28B; interferon lambda 3) gene are strongly associated with sustained viral response (SVR) to PEG-IFN and RBV treatment for chronic hepatitis C [1–3]. Specifically, patients with the TG or GG genotype at rs8099917 infected with genotype 1b are more resistant to PEG-IFN and RBV treatment than patients with the TT

genotype. IL-28B haplotypes were also reported to be strongly associated with spontaneous HCV clearance [1, 4, 5].

IL-28B is a member of the type III IFN family [6], consisting of IFN- λ 1 (IL-29), IFN- λ 2 (IL-28A) and IFN- λ 3 (IL-28B). IFN- λ s bind to their cognate receptor, composed of IL28R1 and IL10R2, and then activate the receptor-associated Janus-activated kinases (Jak) 1 and tyrosine kinase (Tyk) 2, leading to the activation of downstream signal transducer and activator of transcription (STAT) proteins, STAT1 and STAT2. Similar to type I IFN signalling, the Jak-STAT signalling pathway activates the IFN-stimulated response element (ISRE) within the promoter region of interferon-stimulated genes (ISGs) [7].

Concerning the functional role of IL-28B in HCV infection, two of *in vivo* studies assessed the correlation of IL-28A/B mRNA levels in whole blood and peripheral blood mononuclear cells (PBMC) with IL-28B haplotypes at position rs8099917. IL-28A mRNA and IL-28B mRNA levels in subjects with the TT genotype were higher than in subjects with other genotypes (TG or GG), suggesting an association between higher amounts of endogenous IFN- λ s and HCV clearance [2, 3]. On the other hand, subjects

Abbreviations: DMEM, Dulbecco's modified Eagle's medium; FBS, foetal bovine serum; ISG, interferon-stimulated genes; MTS, dimethylthiazol carboxymethoxyphenyl sulphophenyl tetrazolium; PBMC, peripheral blood mononuclear cells; SNP, single-nucleotide polymorphisms; STAT, signal transducer and activator of transcription; SVR, sustained viral response.

Correspondence: Shinya Maekawa, M.D., Ph.D., First Department of Internal Medicine, University of Yamanashi, 1110, Shimokato, Chuo, Yamanashi 409-3898, Japan. E-mail: maekawa@yamanashi.ac.jp

with the TT genotype at SNP rs8099917 were reported to have lower expression levels of ISGs in the liver during the pretreatment period as compared with subjects with the TG or GG genotypes [8]. Several *in vitro* studies support a direct role of IFN- λ s in the control of HCV replication through the innate immune pathway. In a cell culture system, Marcello *et al.* [9] showed that IFN- λ 1 inhibited HCV replication with similar kinetics to that of IFN- α , although IFN- λ 1 induced stronger upregulation of ISGs and this effect lasted longer. Moreover, combinations of IFN- λ 1 and IFN- α had a greater inhibitory effect on HCV replication compared with the individual agents [10].

As suggested by the studies performed to date, a change in IFN- λ 3 expression might be a key mechanism by which IL-28B SNPs determine the response to PEG-IFN and RBV. Considering that IFN- λ 1 plays a direct role in the control of HCV replication and that IFN- λ 1 enhances the antiviral activity of IFN- α , it seems reasonable to speculate that IFN- λ 3 plays a similar antiviral role. Therefore, in this study, we investigated the direct antiviral role of IFN- λ 3 alone and in combination with IFN- α using an HCV replicon system. In addition, we used microarray analysis to investigate the influence of IFN- λ 3, alone or in combination with IFN- α , on the regulation of ISG-mediated antiviral pathways.

MATERIALS AND METHODS

Cell culture and HCV replicon

The human hepatoma cell lines OR6 and Huh7.5.1 were maintained in Dulbecco's modified Eagle's medium (DMEM; Sigma, St. Louis, MO, USA) supplemented with 10% foetal bovine serum (FBS) at 37°C in 5% CO₂. JFH-1-infected Huh7.5.1 cells were grown in DMEM supplemented with 10% FBS. The OR6 cell line, harbouring full-length genotype 1b HCV RNA and co-expressing *Renilla* luciferase (ORN/C-5B/KE) [11], was established in the presence of 500 µg/mL G418 (Promega, Madison, WI, USA).

Reagents

IL-28A (IFN- λ 2), IL-28B (IFN- λ 3) and IL-29 (IFN- λ 1) were obtained from R&D Systems (Minneapolis, MN, USA). IL-28A and IL-29 are recombinant proteins generated from an NSO-derived murine myeloma cell line, and IL-28B is a recombinant protein generated from the CHO cell line. Interferon alpha-2b (INTRON[®]A 300 IU) was obtained from Schering-Plough Corporation (Kenilworth, NJ, USA).

Reporter plasmids and luciferase assay

HCV replication in OR6 replicon cells was determined by monitoring *Renilla* luciferase activity (Promega). To monitor IFN signalling directed by the interferon-stimulated response element (ISRE), the plasmids pISRE-luc expressing

firefly luciferase were cotransfected using FuGENE[®]6 Transfection Reagent (Roche, Indianapolis, IN, USA) following the manufacturer's protocol. Luciferase activity was quantified using the dual-luciferase assay system (Promega) and a GloMax 96 Microplate Luminometer (Promega). Assays were performed in triplicate, and the results were expressed as mean \pm SD percentage of the control values.

Quantification of HCV core protein and RNA

We quantified HCV core protein in culture supernatant using Lumipulse Ortho HCV Ag (Ortho Clinical Diagnostics, Tokyo, Japan) as specified by the manufacturer. The principle of the measurement method is based on the chemiluminescent enzyme immunoassay (CLEIA) [12].

Real-time reverse transcription polymerase chain reaction (RT-PCR)

Intracellular genomic JFH-1 HCV RNA as well as cellular mRNA of IFI-6, IFIT1 (ISG56), DDX60, OAS2, Mx1 and USP18 was quantified by TaqMan RT-PCR. The cells were lysed and subjected to reverse transcription without purification of RNA using a Cells-to-Ct kit (Applied Biosystems, Foster City, CA, USA) according to the manufacturer's protocol. Quantitative PCR was performed in triplicate using a 7500 Real-Time PCR System (Applied Biosystems) and TaqMan Gene Expression Assays (Applied Biosystems) according to the manufacturer's instructions. The sequences of the sense and antisense primers and the TaqMan probe for 5'UTR region of HCV were 5'-TGCGG AACCGGTGAGTACA-3', 5'-CTTAAGGTTTAGGATTCGTGCT CAT-3' and 5'-(FAM)CACCTATCAGGCAGTACCACAAGG CC(TAMRA)-3', respectively. TaqMan probes for IFI-6, IFIT1 (ISG56), DDX60, OAS2, Mx1 and USP18 were purchased from Applied Biosystems. Primers for 18s rRNA (Applied Biosystems) were used as internal control.

Microarray analysis

OR6 replicon cells were harvested by centrifugation after exposure to 0.01 ng/mL IFN- α , 10 ng/mL IFN- λ 3 or a combination of both for 6, 12, 24 and 48 h. Total RNA was isolated from cells using the RNeasy Mini Kit (Qiagen, Valencia, CA, USA). On-column DNase digestion was performed using the RNase-Free DNase Set (Qiagen). Quality control of extracted RNA was performed with the 2100 Bioanalyzer (Agilent Technologies, Palo Alto, CA, USA).

The RNA was then amplified and labelled using the Ambion[®] WT Expression Kit and GeneChip[®] WT Terminal Labelling and Control Kit (Affymetrix, Santa Clara, CA, USA). cDNA was synthesized, labelled and hybridized to the GeneChip[®] array according to the manufacturer's protocol, starting with 200-ng total RNA. The GeneChips were finally washed

and stained using the GeneChip[®] Fluidics Station 450 (Affymetrix) and then scanned with the GeneChip[®] Scanner 3000 7G (Affymetrix).

Affymetrix CEL files were imported into GeneSpring GX v.11.5 (Agilent Technologies, Santa Clara, CA, USA) analysis software. Data were normalized using robust multichip average analysis (RMA).

Dimethylthiazol carboxymethoxyphenyl sulphophenyl tetrazolium (MTS) assays

To evaluate the cell viability, dimethylthiazol carboxymethoxyphenyl sulphophenyl tetrazolium (MTS) assays were performed using a CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit (Promega) according to the manufacturer's instructions.

Statistical analyses

Statistical analyses were performed using an unpaired, two-tailed Student's *t*-test. *P* values of < 0.05 were considered to be statistically significant.

RESULTS

IFN- λ 1, IFN- λ 2 and IFN- λ 3 demonstrate antiviral activity against HCV

To determine the antiviral effect of IL-29 (IFN- λ 1), IL-28A (IFN- λ 2) and IL-28B (IFN- λ 3) against HCV, OR6/ORN/C-5B/KE cells were seeded in 96-well plates for 24 h and then treated with IFN- λ 1, IFN- λ 2, IFN- λ 3 or IFN- α at various concentrations for another 24, 48 and 72 h. In this system, the *Renilla* luciferase activity reflects the amount of HCV RNA synthesized. As shown in Fig. 1, at concentrations of 1 ng/mL or more, all IFN- λ s led to a concentration- and time-dependent decrease in luciferase activity of the OR6/C-5B replicon. IFN- λ 3 at 10 ng/mL inhibited HCV replication (32% reduction, *P* < 0.05) to a similar extent as 0.01 ng/mL IFN- α (49% reduction, *P* < 0.05) by 48 h.

We also assessed the effects of IFN- λ 1, IFN- λ 2 and IFN- λ 3 on Huh7.5.1/JFH-1 cells. JFH-1 cells were seeded in 96-well plates for 24 h and then treated with IFN- λ 1, IFN- λ 2, IFN- λ 3 or IFN- α at various doses for another 48 h. To determine their antiviral effect, HCV core protein in the medium and intracellular HCV RNA were measured by CLEIA and quantitative real-time RT-PCR, respectively. HCV RNA quantitative PCR assays were multiplexed for 18S ribosomal RNA to control for the amount of input RNA. As shown in Fig. 2, all IFN- λ s inhibited HCV replication in JFH-1 cells in a concentration-dependent manner. Similarly, all of the IFN- λ s caused suppression of HCV core protein secretion into the cell culture medium (Figure S1).

In C-5B system, there was no evident cytotoxicity below 100 ng/mL in any interferons except for IFN- λ 1 (Figure

S2). On the other hand, cytotoxicity was observed in lesser concentrations by those IFNs in JFH-1 system. However, as demonstrated in Fig. 2 and Figure S3, antiviral effect exceeded the cytotoxicity in the JFH-1 system.

Synergistic inhibition of HCV replication by IFN- λ 3 and IFN- α in combination

We examined whether the combination of IFN- λ 3 and IFN- α induces greater antiviral activity as compared with the individual cytokines alone. OR6/ORN/C-5B/KE cells were treated with the combinations of IFN- λ 3 and IFN- α at various concentrations for 48 h. As shown in Fig. 3a, the relative concentration-inhibition curves of IFN- α were plotted for each fixed concentration of IFN- λ 3, and the curves shifted to the left with increasing concentrations of IFN- λ 3. The results indicate a synergistic effect of IFN- λ 3 and IFN- α against HCV replication. We confirmed the synergistic effect of IFN- λ 3 and IFN- α by isobologram (Fig. 3b). The inhibitory effects of the combination were quantified according to the method of Chou *et al.* using the CalcuSyn software program (Biosoft, Cambridge, UK). At the ED₅₀ of each drug, the combination index was 0.40-0.61, indicating significant synergism. We also assessed the effect of the combination on Huh7.5.1/JFH-1 cells by HCV RNA quantitative PCR assays and HCV core protein secretion. At the ED₅₀ of each drug, the combination index was 0.55 and 0.48, respectively (Table S1). The cytotoxicity was not observed at the range of concentration tested (Fig. S2E, S3E).

IFN- λ 3 induces ISRE promoter activity

We used the ISRE luciferase reporter assay to assess activity downstream of the JAK-STAT signalling pathway. The ISRE-firefly luciferase plasmid was transfected into OR6/ORN/C-5B/KE cells for 24 h, and these cells were cultured with various concentrations of IFN- λ 3 and IFN- α for another 12, 24 or 48 h. Firefly and *Renilla* luciferase activity was then measured.

IFN- λ 3 induced ISRE luciferase activity in a time-dependent manner: activity was elevated threefold after treatment with 100 ng/mL IFN- λ 3 for 48 h (Fig. 4). In contrast, IFN- α induced ISRE luciferase more rapidly, producing maximal activation of the response to IFN- α at 12 h. The combination of IFN- λ 3 and IFN- α induced ISRE luciferase activity similarly to IFN- λ 3 alone.

IFN- α and IFN- λ 3 induce expression of similar genes in HCV 1b replicon cells

OR6/ORN/C-5B/KE cells were stimulated for 6, 12, 24 and 48 h with 0.01 ng/mL IFN- α , 10 ng/mL IFN- λ 3 or a combination of both, while controls were left unstimulated for the same time interval. Induction of gene expression by IFNs was analysed in microarray experiments.




Fig. 1 IFN- α and IFN- λ s inhibit HCV replicon in OR6 cells. Specific inhibition of the replication of a full-length HCV genotype 1b replicon by (a) IFN- α and (b) IFN- λ 1, (c) IFN- λ 2, (d) IFN- λ 3 were quantified on the basis of luciferase activity. Symbols show the mean value of triplicate wells; error bars show the SD. *: $P < 0.05$ vs control (IFN 0 ng/mL) of each time point.




Fig. 2 IFN- α and IFN- λ s inhibit HCV replicon in Huh7.5.1 cells. JFH1-infected Huh7.5.1 cells were incubated with various concentrations of (a) IFN- α and (b) IFN- λ 1, (c) IFN- λ 2, (d) IFN- λ 3. After 48 h of treatment, total RNA was isolated and reverse transcribed, after which quantitative PCR was performed. Symbols show the mean value of triplicate wells; error bars show the SD. *: $P < 0.05$ vs control (IFN 0 ng/mL).




Fig. 3 Synergistic inhibitory effect of IFN- λ 3 with IFN- α on hepatitis C virus replication. OR6/ORN/C-5B/KE cells were treated with combinations of IFN- λ 3 with IFN- α at various concentrations. (a) The relative concentration-inhibition curves of IFN- α plotted for each fixed concentration of IFN- λ 3 (0, 1, 10 and 100 ng/mL). (b) Classic isobologram for IC₅₀ of IFN- λ 3 with IFN- α in combination.




Fig. 4 IFN-stimulated response element (ISRE) promoter activity induced by IFN- α , IFN- λ 3 or combination of IFN- α and IFN- λ 3. OR6/ORN/C-5B/KE cells transfected with ISRE-firefly luciferase were cultured with various concentrations of IFN- α alone, IFN- λ 3 alone or 0.01 ng/mL IFN- α plus 10 ng/mL IFN- λ 3. ISRE-firefly luciferase activity at 24 h after transfection. Symbols show the mean value of triplicate wells; error bars show the SD. *: $P < 0.05$.

At all time points, the IFN- λ 3-treated samples showed a tendency for the induction of a larger number of genes than samples treated with IFN- α . However, as shown in Table 1 listing the top 25 genes that were upregulated by both IFN- α and IFN- λ 3 at 12 h, most of the upregulated genes are previously identified ISGs and the genes with high ranks were similar irrespective of the type of IFN or time point.

The time course of ISGs regulation differs between IFN- α and IFN- λ 3

By microarray analysis, ISGs were more rapidly induced after the addition of IFN- α vs IFN- λ 3 (data not shown). To confirm the rapid induction of ISGs by IFN- α , six ISGs, that is, IFI-6, IFIT1 (ISG56), DDX60, OAS2, Mx1 and USP18, were quantified for time-dependent expressional change by real-time RT-PCR. Expression of most of the genes upregulated by IFN- α peaked at 12 h and fell thereafter. In contrast, expression of IFN- λ 3-induced genes peaked at 24 h

and lasted up to 48 h. Combination of IFN- α and IFN- λ 3 induced ISG with peak effects occurring at 12–24 h and lasting up to 48 h (Fig. 5).

DISCUSSION

In this study, we demonstrated that IFN- λ family members have distinctive time-dependent antiviral activities in an HCV replicon system and that IFN- λ 3 and IFN- α have a synergistic effect in combination. Moreover, we attempted to identify the antiviral mechanism of IFN- λ 3 by conducting a cDNA microarray analysis.

In previous studies, anti-HCV activity of IFN- λ 1, IFN- λ 2 and IFN- λ 3 was reported in JFH-1 and OR6/C-5B systems [13]. Time-dependent anti-HCV activity has also been observed with IFN- λ 1 [9]. In this study, we confirmed the previous results and added the further finding that time-dependent antiviral activity is not limited to IFN- λ 1, but rather is common among all IFN- λ s.

Table 1 Top 25 genes that were upregulated by both IFN- α and IFN- λ 3 at 12 h

Gene bank ID	Gene symbol	Gene description	IFN- α 0.01 ng/mL fold increase	IFN- λ 3 10 ng/mL fold increase	IFN- α +IFN- λ 3 fold increase
BC007091	IFIT1	Interferon-induced protein with tetratricopeptide repeats 1	4.01	4.49	4.87
BC049215	OAS2	2'-5'-oligoadenylate synthetase 2, 69/71kDa	3.06	3.88	4.48
M33882	MX1	Myxovirus (influenza virus) resistance 1	3.24	3.29	3.69
AF095844	IFIH1	Interferon induced with helicase C domain 1	2.73	3.02	3.54
BC038115	DDX60	DEAD (Asp-Glu-Ala-Asp) box polypeptide 60	2.70	2.92	3.51
BC011601	IFI6	Interferon, alpha-inducible protein 6	3.07	3.24	3.42
BC042047	HERC6	Hect domain and RLD 6	2.56	2.75	3.34
AF442151	RSAD2	Radical S-adenosyl methionine domain containing 2	1.32	2.59	3.28
U34605	IFIT5	Interferon-induced protein with tetratricopeptide repeats 5	2.47	2.91	3.25
AY730627	OAS1	2'-5'-oligoadenylate synthetase 1, 40/46kDa	2.32	2.57	3.05
AB006746	PLSCR1	Phospholipid scramblase 1	2.37	2.51	3.03
AF307338	PARP9	Poly (ADP-ribose) polymerase family, member 9	2.39	2.46	2.94
M87503	IRF9	Interferon regulatory factor 9	2.61	2.59	2.85
AK297137	IFIT3	Interferon-induced protein with tetratricopeptide repeats 3	1.90	2.36	2.79
AK290655	EIF2AK2	Eukaryotic translation initiation factor 2-alpha kinase 2	2.47	2.45	2.77
BX648758	PARP14	Poly (ADP-ribose) polymerase family, member 14	2.07	2.25	2.66
BC132786	DDX58	DEAD (Asp-Glu-Ala-Asp) box polypeptide 58	1.83	2.17	2.59
AF445355	SAMD9	Sterile alpha motif domain containing 9	2.07	2.08	2.56
	DDX60L	DEAD (Asp-Glu-Ala-Asp) box polypeptide 60-like	1.63	1.92	2.39
BC014896	USP18 ¹ USP41	Ubiquitin-specific peptidase 18/ubiquitin-specific peptidase 41	1.52	1.78	2.11
AB044545	OAS3	2'-5'-oligoadenylate synthetase 3, 100kDa	1.44	1.57	2.10
BC010954	CXCL10	Chemokine (C-X-C motif) ligand 10	0.76	1.66	1.99
BC014896	USP18	Ubiquitin-specific peptidase 18	1.33	1.55	1.99
AL832618	IFI44L	Interferon-induced protein 44-like	0.58	1.31	1.95

We also assessed whether IFN- λ 3 and IFN- α in combination could produce additive or synergistic effects on antiviral activity. In previous studies, additive antiviral activity against HCV was reported with the combination of IFN- λ 1 and IFN- α [9, 10]. However, there have been no previous reports on the combined effects of IFN- λ 3 and IFN- α . In this study, the focus was on IFN- λ 3, because IFN- λ 3 is suspected to be the key molecule, mediating the effect of SNPs

in the IL-28B gene region on the anti-HCV response to IFN- α . As shown in Fig. 3 and Table S1, synergistic induction of anti-HCV activity occurred in both the OR6/C-5B and Huh7.5/JFH-1 HCV replicon systems. Synergy was demonstrated by the combination index values (Table S1).

Although it has been reported that the upregulated genes induced by IFN- λ are similar to those induced by IFN- α [9, 14–16], there have been no previous reports on